Weekly Report: what happened at ICLR last week (1120-1124)?
Weekly Report · 1d ago
ICON: Starting Valuations And Business Returns Are 2 Major Hurdles
Iclr's q3 numbers indicate the market is forecasting a period of better business for the company in 2024. Projected earnings growth out to 2025 is 9-14% on sales growth of 5-7%. Despite a strong company, current multiples are expensive. Icon is a hold because of its valuation and lack of business returns.
Seeking Alpha · 1d ago
ICON (NASDAQ:ICLR) shareholders have earned a 14% CAGR over the last five years
Icon public limited company's share price is up 92% in the last 5 years, besting the market return of 62%. Icon has a total shareholder return of 25% over the last 12 months. The company has grown its earnings per share at 2.0% a year, but not at the rate of the market. Icon's earnings growth does not match the performance of the company's underlying business.
Simply Wall St · 5d ago
ICON PLC: Report of proposed sale of securities
Press release · 6d ago
3 Reasons Growth Investors Will Love Icon PLC (ICLR)
NASDAQ · 11/20 17:45
Weekly Report: what happened at ICLR last week (1113-1117)?
Weekly Report · 11/20 09:20
ICON PLC: Report of proposed sale of securities
Press release · 11/17 01:00
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Becton Dickinson (BDX) and McKesson (MCK)
3 analysts have maintained buy ratings on icon (iclr), becton dickinson (bdx) and mckesson. Jefferies analyst david windley maintained a buy rating on icon yesterday. Bect on dickinson has also been reiterated as a buy in a report released by jefferies.
TipRanks · 11/15 13:30
Weekly Report: what happened at ICLR last week (1106-1110)?
Weekly Report · 11/13 09:19
ICLR or DOCS: Which Is the Better Value Stock Right Now?
NASDAQ · 11/10 16:40
Polen Global Growth Q3 2023 Commentary
Polen global growth composite portfolio was down -3.19% gross and net of fees in q3 2021. The market is focused on central banks and speculation. Polen capital is a global independently-owned growth equity boutique. Etpolen global growth fund institutional class: pgiix.
Seeking Alpha · 11/10 14:35
With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Icon (nasdaq:iclr) has grown its earnings per share by 9.5% in the last year. The company is growing its revenue by 4.6%. Icon has modest ceo pay and considerable insider ownership of the company. Ceo compensation is reasonable for a company of its size. Icon produces revenue of us$8.0b but is growing at a faster rate than the market.
Simply Wall St · 11/08 17:48 featured highlights include Confluent, Pinterest, ICON and ImmunoGen
NASDAQ · 11/08 13:08
ICON PLC: Report of foreign issuer
Press release · 11/08 12:00
ICON PLC: Report of proposed sale of securities
Press release · 11/08 00:00
4 Stocks to Invest in for Remarkable Earnings Acceleration
NASDAQ · 11/07 11:56
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Shockwave Medical (SWAV), Icon (ICLR) and Vertex Pharmaceuticals (VRTX)
Analysts have maintained hold ratings on shockwave medical, icon and vertex pharmaceuticals. wells fargo maintained a buy rating on vertex pharmaceuticals yesterday. icon has been recommended as a strong buy by analysts for the healthcare sector, according to tipranks. the analysts have also maintained their ratings onshockwave medical and icon.
TipRanks · 11/07 10:22
Weekly Report: what happened at ICLR last week (1030-1103)?
Weekly Report · 11/06 09:19
Baron Small Cap Fund Q3 2023 Shareholder Letter
Seeking Alpha · 11/05 14:20
Webull provides a variety of real-time ICLR stock news. You can receive the latest news about ICON PLC through multiple platforms. This information may help you make smarter investment decisions.
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.